ALK-positive lung cancer

The FDA ( U.S. Food and Drug Administration ) has approved supplemental New Drug Application ( sNDA ) for Lorbrena...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...


Researchers have retrospectively examined progression-free survival ( PFS ) and response by ALK fluorescence in-situ hybridization ( FISH ) status...


Lorlatinib ( Lorviqua ) is a 3rd-generation ALK tyrosine kinase inhibitor ( TKI ) developed to penetrate the central nervous...


Ensartinib is a novel second-generation ALK tyrosine kinase inhibitor ( TKI ). In phase 1/2 studies, Ensartinib showed promising activity...


The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada...


The European Commission ( EC ) has approved Alecensa ( Alectinib ), a second-generation ALK inhibitor, for the frontline treatment...


The aim of a study was to explore the efficacy and safety of Crizotinib ( Xalkori ) versus Platinum-based double...


The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...


Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening...


Positive results from two phase II studies that evaluated the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people...


The FDA ( U.S. Food and Drug Administration ) has approved Alecensa ( Alectinib ) to treat people with advanced...


In the large pivotal phase II study, BIRCH, the investigational cancer immunotherapy Atezolizumab ( MPDL3280A; anti-PD-L1 ) met its primary...


The FDA ( Food and Drug Administration ) has approved a new second-generation lung cancer treatment that can help many...


Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias...


Results from two pivotal studies ( NP28673 and NP28761 ) have showen Alectinib, an oral investigational anaplastic lymphoma kinase inhibitor...


The efficacy of the ALK inhibitor, Crizotinib ( Xalkori ) as compared with standard chemotherapy as first-line treatment for advanced...


In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene ( ALK ) have been associated with marked clinical...